As of close of business last night, Summit Therapeutics Inc’s stock clocked out at $4.48, down -3.66% from its previous closing price of $4.65. In other words, the price has decreased by -$0.1700 from its previous closing price. On the day, 863029 shares were traded.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Ratios:
To gain a deeper understanding of SMMT’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 9.30 and its Current Ratio is at 9.30. In the meantime, Its Debt-to-Equity ratio is 1.37 whereas as Long-Term Debt/Eq ratio is at 1.33.
Needham reiterated its Buy rating for the stock on April 12, 2018, while the target price for the stock was revised from $30 to $27.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Dec 13 when Dhingra Ankur bought 20,400 shares for $2.17 per share. The transaction valued at 44,254 led to the insider holds 254,958 shares of the business.
Zanganeh Mahkam bought 5,000 shares of SMMT for $10,350 on Dec 12. The Chief Executive Officer now owns 494,814 shares after completing the transaction at $2.07 per share. On Oct 13, another insider, Soni Manmeet Singh, who serves as the Chief Operating Officer of the company, bought 2,976,190 shares for $1.68 each. As a result, the insider paid 4,999,999 and bolstered with 2,976,190 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SMMT now has a Market Capitalization of 3.26B and an Enterprise Value of 3.18B. Its current Enterprise Value per Revenue stands at 6.43k whereas that against EBITDA is -5.34.
Stock Price History:
Over the past 52 weeks, SMMT has reached a high of $5.14, while it has fallen to a 52-week low of $1.25. The 50-Day Moving Average of the stock is 3.6744, while the 200-Day Moving Average is calculated to be 2.3829.
Shares Statistics:
It appears that SMMT traded 1.91M shares on average per day over the past three months and 2.18M shares per day over the past ten days. A total of 701.66M shares are outstanding, with a floating share count of 82.51M. Insiders hold about 88.24% of the company’s shares, while institutions hold 4.64% stake in the company. Shares short for SMMT as of Feb 15, 2024 were 12.75M with a Short Ratio of 6.66, compared to 10.82M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 1.82% and a Short% of Float of 15.31%.
Earnings Estimates
As of right now, 0 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of $0 for the current quarter, with a high estimate of $0 and a low estimate of $0, while EPS last year was -$1.24. The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.
Analysts are recommending an EPS of between $0 and $0 for the fiscal current year, implying an average EPS of $0. EPS for the following year is $0, with 0 analysts recommending between $0 and $0.
Revenue Estimates
A total of 1 analysts have provided revenue estimates for SMMT’s current fiscal year. The highest revenue estimate was $1.56M, while the lowest revenue estimate was $1.56M, resulting in an average revenue estimate of $1.56M. In the same quarter a year ago, actual revenue was $20.17M, down -92.30% from the average estimate.
